Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.
Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou, China.
Front Immunol. 2022 Mar 18;13:840956. doi: 10.3389/fimmu.2022.840956. eCollection 2022.
A bibliometric and knowledge-map analysis is used to explore hotspots' evolution and development trends in the CAR-T cell field. By looking for research hotspots and new topics, we can provide new clues and ideas for researchers in this field.
The articles and reviews regarding CAR-T cells were retrieved and obtained from the Web of Science Core Collection (WOSCC) on October 28th, 2021. CtieSpace [version 5.8.R3 (64-bit)] and VOSviewer (version 1.6.17) were used to conduct the bibliometric and knowledge-map analysis.
660 authors from 488 institutions in 104 countries/regions published 6,867 papers in 1,212 academic journals. The United States was absolutely in the leading position in this research field. The institution that contributed the most publications was the University of Pennsylvania. Carl H June published the most articles, while Shannon L Maude had the most co-citations. However, there was little cooperation between countries. After 2012, cooperation among various institutions was also small. The journals that published the most CAR-T cell-related papers were and . Nevertheless, and were the most commonly co-cited journals. The most influential research hotspots were the research of CAR-T cells in hematological malignancies, the related research of cytokine release syndrome (CRS), CD19, and the anti-tumor activity and efficacy of CAR-T cells. The latest hotspots and topics included the study of CAR-T cells in solid tumors, universal CAR-T cells, CAR-NK cells, CD22, and anakinra (the IL-1 receptor antagonist). The research of CAR-T cells in solid tumors was a rapidly developing hot field. Emerging topics in this field mainly included the study of CAR-T cells in glioblastoma (related targets: IL13Rα2, EGFRvIII, and HER2), neuroblastoma (related target: GD2), sarcoma (related target: HER2), and pancreatic cancer (related target: mesothelin), especially glioblastoma.
As an anti-tumor therapy with great potential and clinical application prospects, CAR-T cell therapy is still in a stage of rapid development. The related field of CAR-T cells will remain a research hotspot in the future.
通过文献计量学和知识图谱分析，探讨嵌合抗原受体 T 细胞（CAR-T 细胞）领域的热点演变和发展趋势。通过寻找研究热点和新课题，为该领域的研究人员提供新的线索和思路。
于 2021 年 10 月 28 日检索并获取来自 Web of Science 核心合集（WOSCC）的有关 CAR-T 细胞的文章和综述。使用 CiteSpace [版本 5.8.R3（64 位）]和 VOSviewer（版本 1.6.17）进行文献计量学和知识图谱分析。
来自 104 个国家/地区的 488 个机构的 660 位作者在 1212 种学术期刊上发表了 6867 篇论文。美国在该研究领域绝对处于领先地位。发表文献最多的机构是宾夕法尼亚大学。发表文章最多的作者是 Carl H June，而被引频次最多的是 Shannon L Maude。然而，各国之间的合作很少。2012 年后，各机构之间的合作也很少。发表 CAR-T 细胞相关论文最多的期刊是 和 。然而， 和 是被引用最多的期刊。最具影响力的研究热点是血液恶性肿瘤中 CAR-T 细胞的研究、细胞因子释放综合征（CRS）、CD19 的相关研究以及 CAR-T 细胞的抗肿瘤活性和疗效。最新的热点和课题包括实体瘤中 CAR-T 细胞的研究、通用型 CAR-T 细胞、CAR-NK 细胞、CD22 和 anakinra（白细胞介素 1 受体拮抗剂）。实体瘤中 CAR-T 细胞的研究是一个快速发展的热点领域。该领域的新兴课题主要包括胶质母细胞瘤（相关靶点：IL13Rα2、EGFRvIII 和 HER2）、神经母细胞瘤（相关靶点：GD2）、肉瘤（相关靶点：HER2）和胰腺癌（相关靶点：间皮素）中 CAR-T 细胞的研究，尤其是胶质母细胞瘤。
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。未来，CAR-T 细胞相关领域仍将是研究热点。
